2018 International Congress Archives - Page 42 of 177

1:45pm-3:15pm: Olfactory dysfunction predicting cognition

X. Yu (Cleveland, OH, USA)

Cognitive Disorders · Hall 3FG

1:45pm-3:15pm: Oligosymptomatic Fahr’s syndrome (2 clinical cases)

Y. Solodovnikova (Odessa, Ukraine)

Rare Genetic and Metabolic Diseases · Hall 3FG

1:45pm-3:15pm: On Converting Patients From Oral Dopamine Agonists to the Carbidopa/Levodopa Enteral Suspension Method – Real World Conversion Ratios

S. Nakano, L. Bahroo, F. Pagan, F. Amjad, S. Lo, I. Gambhir (Washington, D.C., DC, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Ondansetron, a highly-selective 5-HT3 receptor antagonist, alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

C. Kwan, I. Frouni, D. Bédard, A. Hamadjida, P. Huot (Montreal, QC, Canada)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Open-label extension (OLE) of a multiple ascending dose (MAD) study of BIIB092 in participants with PSP: Safety analysis

T. Dam, L. Zhang, I. Qureshi, M. Grundman, G. Tirucherai, C. Bechtold, M. Ahlijanian, L. Golbe, L. Honig, S. Isaacson, M. Grossman, N. McFarland, I. Litvan, D. Geldmacher, T. Xie, Y. Bordelon, P. Tuite, P. O’Suilleabhain, T. Zesiewicz, B. Han, A. Boxer (Cambridge, MA, USA)

Clinical Trials and Therapy in Movement Disorders · Hall 3FG

1:45pm-3:15pm: Optimized Imaging at 3.0 T of the Rostral Zona Incerta (rZI) for Deep Brain Stimulation (DBS) in Parkinson’s Disease (PD)

A. Thaker, K. Reddy, J. Thompson, P. David-Gerecht, A. Abosch, D. Kern (Aurora, CO, USA)

Surgical Therapy: Parkinson's Disease · Hall 3FG

1:45pm-3:15pm: Optimizing the Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) outcome in Parkinson’s disease patient with interleaving stimulation

C. Lau, C. Zhu, D. Chan, K. Ma, A. Chan, J. Yeung, V. Mok, W. Poon (Hong Kong)

Surgical Therapy: Parkinson's Disease · Hall 3FG

1:45pm-3:15pm: Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy

P. Howson, T. Johnston, J. Brotchie, M. Hill, J. Koprich (Toronto, ON, Canada)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Oral treatment with sphingosine-1-phosphate receptors modulator prevents Parkinson symptoms concomitantly to reduced brain inflammation in MPTP mouse models

M. Cyr, E. Pépin, G. Massicotte (Trois-Rivieres, QC, Canada)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Outcomes of a Prospective, Multi-center International Registry of Deep Brain Stimulation for Parkinson’s Disease

G. Deuschl, R. Jain, H. Scholtes, A. Wang, M. Barbe, S. Paschen, A. Andrea Kühn, M. Pötter-Nerger, J. Volkmann, J. Vesper (Kiel, Germany)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG